Ramon Parsons, MD, PhD @Ramon_Parsons of @IcahnMountSinai discusses a novel agent that degrades a protein called EZH2 that drives the growth of triple negative breast cancer in cancer cell lines and live models. This research also showed that the agents which inhibit the enzymatic activity of EZH2 but do not degrade EZH2 did not work in triple negative breast cancer.
EZH2 in Triple Negative Breast Cancer @Ramon_Parsons @IcahnMountSinai
